GSA Capital Partners LLP bought a new position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 202,160 shares of the specialty pharmaceutical company’s stock, valued at approximately $651,000. GSA Capital Partners LLP owned approximately 0.13% of Antares Pharma as of its most recent SEC filing.
Several other large investors have also made changes to their positions in ATRS. Wells Fargo & Company MN grew its position in shares of Antares Pharma by 21.6% during the 1st quarter. Wells Fargo & Company MN now owns 767,600 shares of the specialty pharmaceutical company’s stock worth $2,180,000 after purchasing an additional 136,600 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Antares Pharma by 20.1% during the 1st quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock worth $476,000 after purchasing an additional 28,029 shares in the last quarter. M&T Bank Corp acquired a new position in shares of Antares Pharma during the 1st quarter worth approximately $227,000. California Public Employees Retirement System grew its position in shares of Antares Pharma by 14.4% during the 1st quarter. California Public Employees Retirement System now owns 934,300 shares of the specialty pharmaceutical company’s stock worth $2,653,000 after purchasing an additional 117,300 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Antares Pharma by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock worth $15,958,000 after purchasing an additional 232,349 shares in the last quarter. Hedge funds and other institutional investors own 36.77% of the company’s stock.
Shares of Antares Pharma, Inc. (NASDAQ:ATRS) opened at 3.89 on Friday. The firm’s market cap is $608.42 million. The company’s 50 day moving average is $3.14 and its 200 day moving average is $2.97. Antares Pharma, Inc. has a 52-week low of $1.41 and a 52-week high of $3.97.
Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The business had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Analysts anticipate that Antares Pharma, Inc. will post ($0.11) earnings per share for the current year.
In related news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 11.60% of the company’s stock.
WARNING: This piece of content was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/10/08/gsa-capital-partners-llp-buys-shares-of-202160-antares-pharma-inc-atrs.html.
Several analysts recently issued reports on the stock. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a research report on Wednesday, July 5th. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Chardan Capital assumed coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target on the stock. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $4.34.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.